ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Perioperative targeted therapy for oncogene-driven NSCLC

Liu, Si -Yang; Zhang, Jia-Tao; Zeng, Kang-Hui; Wu, Yi-Long*广东省人民医院
Lung Cancer2022-10DOI: 10.1016/j.lungcan.2022.05.007
16被引9阅读
引用收藏
分享

摘要

Targeted therapy has stepped into the perioperative treatment arena and launched a radical revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer (NSCLC). A series of practice-changing clinical trials has enriched the therapeutic perspectives of potentially curable NSCLC. While the CTONG1104 trial took the first step in investigating the adjuvant gefitinib - a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), for the treatment of resected EGFR-mutated NSCLC - the sub-sequent ADAURA study marked adjuvant osimertinib as the standard of care for resected EGFR-mutant NSCLC. Other targeted agents matched for ALK, ROS1, NTRK, BRAF V600, and RET molecular alterations are also currently being evaluated in the adjuvant and neoadjuvant settings, and there is an urgent need to study biomarker selection, optimal duration, and paradigm making. All these efforts are intended to hit the same target, which is to treat patients on a more personalized level.We review herein the recent major breakthroughs in perioperative targeted therapy for oncogene-driven NSCLC, focusing especially on data from published clinical trials. We discuss challenges from surgical, patho-logical, and oncological perspectives, and provide recommended strategies for the clinical management of early -stage NSCLC patients.

学科与关键词

关键词
NeoadjuvantAdjuvantTargeted therapyNSCLC
相关
加载中…
  • Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Grohe, C.; Herbst, R. S.; Tsuboi, M.; John, T.; Majem, M.; Goldman, J. W.; Kim, S. -W.; Marmol, D.; Rukazenkov, Y.; Wu, Y. -L.; Engel-Riedel, W.
  • Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Tsuboi, Masahiro; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan Wade; Kim, Sang-We; Marmol, Dominika; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 52
  • Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.; Tsuboi, Masahiro; John, Tom; Kato, Terufumi; Majem, Margarita; Grohe, Christian; Wang, Jie; Goldman, Jonathan W.; Lu, Shun; Su, Wu-Chou; De Marinis, Filippo; Shepherd, Frances A.; Lee, Ki Hyeong; Le, Nhieu; Dechaphunkul, Arunee; Kowalski, Dariusz M.; Poole, Lynne; Stachowiak, Marta; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 12
查看全部 →

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2022-10
卷期
第 172 卷
页码
160-169
DOI
10.1016/j.lungcan.2022.05.007
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; Guangdong Provincial People?s Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province [KJ012019426]; National Natural Science Foundation of China [82002413]

作者

  • L

    Liu, Si -Yang (第一作者)

    guangdong prov peoples hosp

  • Z

    Zhang, Jia-Tao

    guangdong prov peoples hosp

查看全部 4 位作者收起作者
  • Z

    Zeng, Kang-Hui

    guangdong prov peoples hosp

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417